The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease

Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)

(2016) Henning Grønbæk et al.   JOURNAL OF HEPATOLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery

(2015) Konstantin Kazankov et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease

(2015) Jessica L Mueller et al.   Clinical and Translational Gastroenterology

Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study

(2014) Thomas Damgaard Sandahl et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C

(2014) Konstantin Kazankov et al.   HEPATOLOGY

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

(2014) Pierre Bedossa et al.   HEPATOLOGY

Macrophage heterogeneity in liver injury and fibrosis

(2014) Frank Tacke et al.   JOURNAL OF HEPATOLOGY

Intrahepatic fat content correlates with soluble CD163 in relation to weight loss induced by Roux-en-Y gastric bypass

(2014) Karen Fjeldborg et al.   Obesity

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments

(2013) R. Kwok et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hepatic macrophage activation predicts clinical decompensation in chronic liver disease

(2013) Anthony Rode et al.   GUT

Structural Basis for Inflammation-driven Shedding of CD163 Ectodomain and Tumor Necrosis Factor-α in Macrophages

(2013) Anders Etzerodt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis

(2013) Oliver Waidmann et al.   JOURNAL OF HEPATOLOGY

The Macrophage-Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss

(2013) Karen Fjeldborg et al.   Obesity

Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans

(2013) Michiko Itoh et al.   PLoS One

Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis

(2012) H. Grønbaek et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Soluble CD163: a biomarker linking macrophages and insulin resistance

(2012) T. Parkner et al.   DIABETOLOGIA

Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-induced Mouse Model through Tumor Necrosis Factor-α Production

(2012) Annie-Carole Tosello-Trampont et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States

(2012) Zobair M. Younossi et al.   MEDICINE

Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS

(2011) P. Holland-Fischer et al.   GUT

Soluble CD163

(2011) Holger J. Møller   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Serum Soluble CD163 Predicts Risk of Type 2 Diabetes in the General Population

(2010) H. J. Moller et al.   CLINICAL CHEMISTRY

Increased tumor necrosis factor α-converting enzyme activity induces insulin resistance and hepatosteatosis in mice

(2009) Loredana Fiorentino et al.   HEPATOLOGY

Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity

(2009) Rinke Stienstra et al.   HEPATOLOGY

Kupffer cells in non-alcoholic fatty liver disease: The emerging view

(2009) György Baffy   JOURNAL OF HEPATOLOGY